Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.

Background: Prolgolimab is an IgG1 anti-PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing 'LALA' mutation. We assessed the efficacy and safety of two dosing regimens of prolgolimab in patients with advanced melanoma in a multicenter open-label parallel-arm phase II trial (MIRACULUM). We present the final analysis after 1 year of follow-up and additional efficacy results from 2 years of follow-up.

A Comparison of Remote and Bedside Assessment of the National Institute of Health Stroke Scale in Acute Stroke Patients.

Introduction: Telestroke videoconference for conducting the National Institute of Health Stroke Scale (NIHSS) is recommended when the facility of a direct bedside evaluation by a stroke specialist is not immediately available for hyperacute stroke assessment. However, some NIHSS-telestroke studies inherit systematic bias due to the subjective nature of NIHSS administration. We aimed to evaluate NIHSS telestroke assessment, while implementing measures to minimize subjectivity bias.

Direct electrophilic silylation of terminal alkynes.

[reaction: see text] A variety of alkynylsilanes were efficiently prepared via direct silylation of terminal alkynes with aminosilanes in the presence of zinc halides. Base- and nucleophile-sensitive functionalities were perfectly tolerated under the above reaction conditions. Initial mechanistic studies support the electrophilic character of this transformation.